Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Citius OncologyCTOR -0.94%10 Equity-to-Asset is 0.35 as of Mar. 2026, which is 24% below its 10-year median of 0.46. GuruFocus rates CTOR with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Citius Oncology ranks worse than 80.24% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Citius Oncology's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $35.27 Mil. Citius Oncology's Total Assets for the quarter that ended in Mar. 2026 was $100.70 Mil.
Therefore, Citius Oncology's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.35.
The historical rank and industry rank for Citius Oncology's Equity-to-Asset or its related term are showing as below:
CTOR'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.35 Med: 0.46 Max: 0.85
Current: 0.35
During the past 4 years, the highest Equity to Asset Ratio of Citius Oncology was 0.85. The lowest was 0.35. And the median was 0.46.
CTOR's Equity-to-Asset is ranked worse than 80.24% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs CTOR: 0.35
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Citius Oncology Equity-to-Asset Related Terms
Citius Oncology Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Citius Oncology's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CTOR vs INCR, CPHI, SCYX: Equity-to-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Citius Oncology's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Citius Oncology Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Citius Oncology's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Citius Oncology's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Citius Oncology's Equity to Asset Ratio for the fiscal year that ended in Sep. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Citius Oncology (CTOR) has a Equity-to-Asset of 0.35 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Citius Oncology and its competitors. This is 24% below median its historical median of 0.46. Over the past decade, Citius Oncology's Equity-to-Asset has ranged from 0.35 to 0.85. According to the industry distribution chart, Citius Oncology ranks #808 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 80.2%.
Is Citius Oncology's Equity-to-Asset too high?
Citius Oncology's current Equity-to-Asset of 0.35 is 24% below median its 10-year median of 0.46. Over the past 10 years, this metric has ranged from a low of 0.35 to a high of 0.85. The Drug Manufacturers industry median Equity-to-Asset is 0.61. Citius Oncology's value of 0.35 is 42.6% below this industry median. Based on the distribution chart, Citius Oncology ranks #808 out of 1007 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Citius Oncology has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Citius Oncology's Equity-to-Asset compare to INCR and CPHI?
According to the Drug Manufacturers industry distribution chart, Citius Oncology ranks #808 out of 1007 companies for Equity-to-Asset. This places Citius Oncology in the lower half of its industry. The industry median Equity-to-Asset is 0.61. Citius Oncology's value of 0.35 is 42.6% below this benchmark. Historically, Citius Oncology's own Equity-to-Asset has ranged from 0.35 to 0.85 over the past decade. While the company's 10-year median is 0.46 vs. the industry median of 0.61, Citius Oncology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Citius Oncology's current Equity-to-Asset of 0.35 is 42.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Citius Oncology and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Citius Oncology's current Equity-to-Asset is 0.35, which is 24% below median its own 10-year median of 0.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Citius Oncology stock overvalued right now?
Citius Oncology (CTOR) has a current Equity-to-Asset of 0.35. The current Equity-to-Asset is 0.35, which is 24% below median its 10-year median of 0.46 and 42.6% below the Drug Manufacturers industry median of 0.61. Citius Oncology's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Citius Oncology (CTOR), the current Equity-to-Asset is 0.35 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.
10GF Score
Get the complete analysis for CTOR
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTOR has been successfully added to your 
